Treating HIV-Associated Lymphoma
Joseph Alvarnas, MD, Director of Medical Quality, associate clinical professor, City of Hope, discusses the treatment of HIV-associated lymphoma.
Clinical Pearls
Joseph Alvarnas, MD, Director of Medical Quality, associate clinical professor, City of Hope, discusses the treatment of HIV-associated lymphoma.
- The most appropriate way to treat patients with HIV and lymphoma has been a quandary for years.
- This study looked at autologous hematopoietic stem cell transplantation for the treatment of patients with chemotherapy-sensitive, relapsed/refractory HIV-associated lymphoma.
- Estimated probability of one-year OS was 86.6%.
<<<
Evaluating Role of Loncastuximab in Third-Line DLBCL After CAR T
May 7th 2025During a live event, Krish Patel, MD, discussed barriers to using bispecific T-cell engagers and practical considerations of using loncastuximab in a patient with relapsed diffuse large B-cell lymphoma who had prior CAR T-cell therapy.
Read More
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Prior Pelvic Radiation Linked to Higher Complications After Bladder Cancer Surgery
April 30th 2025Bladder cancer patients undergoing radical cystectomy after pelvic radiotherapy showed increased risks of rectal injury, readmission, sepsis, and surgical-site infections compared with primary surgery.
Read More
